Search - tctmd.com

Displaying 61 - 80 of 205

Sort: Relevancy | Date

News Daily News

AHA Scientific Statement Addresses Health Disparities in PAD

L.A. McKeown

June 23, 2023

News Opinion CV Team Dispatch

June 2023 News Roundup

L.A. McKeown

June 01, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

Think Differently: Diabetes, CVD Risks in Asian Americans Not Uniform, AHA Says

Caitlin E. Cox

May 09, 2023

News Daily News

To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC

Yael L. Maxwell

April 12, 2023

News Daily News

Inactivity Pandemic Poised to Undo CVD Prevention Advances

Michael O'Riordan

April 11, 2023

News Opinion CV Team Dispatch

April 2023 News Roundup

L.A. McKeown

April 01, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

News Daily News

Autism and Cardiometabolic Disease Often Go Hand in Hand

Caitlin E. Cox

February 06, 2023

News Daily News

AHA Annual Statistics Show COVID’s Disruptive Impact

L.A. McKeown

January 30, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Daily News

ACC’s Valve Staging Tool Reveals Silent Disease is Common in the Elderly

L.A. McKeown

December 22, 2022

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

Advertisement

AHA Scientific Statement Addresses Health Disparities in PAD

June 2023 News Roundup

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Think Differently: Diabetes, CVD Risks in Asian Americans Not Uniform, AHA Says

To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC

Inactivity Pandemic Poised to Undo CVD Prevention Advances

April 2023 News Roundup

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Autism and Cardiometabolic Disease Often Go Hand in Hand

AHA Annual Statistics Show COVID’s Disruptive Impact

January 2023 News Roundup

ACC’s Valve Staging Tool Reveals Silent Disease is Common in the Elderly

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content